Latest Breaking News On - Molecular templates - Page 7 : comparemela.com

vTv Therapeutics (VTVT) Appoints Thomas Strack as Chief Medical Officer

vTv Therapeutics (VTVT) Appoints Thomas Strack as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Thomas strackPaul sekhriEli lilly companyProgenics pharmaceuticalsAffairs at molecular templates incConsultant in medical affairs at omeros corporationFaeth therapeutics incAsubio pharmaceuticals incJohannes gutenberg universityClinical research physician in lilly laboratoriesClinical developmentTv therapeutics incUs regulatory affairsChief medical officerChief executive officerSenior vice president

vTv Therapeutics Appoints Thomas Strack, M D , as Chief Medical Officer

vTv Therapeutics Appoints Thomas Strack, M D , as Chief Medical Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Paul sekhriSelina husainRobert flammThomas strackLee rothDburns mcclellanTv therapeutics incFaeth therapeutics incAffairs at molecular templates incClinical developmentEli lilly companyAsubio pharmaceuticals incClinical research physician in lilly laboratoriesUs regulatory affairsJohannes gutenberg universityProgenics pharmaceuticals

Molecular Templates Announces First Patient Dosed in Phase

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage.

United statesEric pomaExchange commissionMolecular templates incAntigen seeding technologyMicrosatellite instability highMismatch repair deficientChief executiveChief scientific officerShiga like toxinPrivate securities litigation reform actMolecular templatesSafe harborMolecular templateQuarterly reportNasdaq mtem

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesEric pomaMolecular templates incExchange commissionAntigen seeding technologyTemplates announces first patient dosedNovel engineered toxin body targetingAdvanced solidMicrosatellite instability highMismatch repair deficientChief executiveChief scientific officerShiga like toxinPrivate securities litigation reform actMolecular templatesSafe harbor

Molecular Templates to Participate in Upcoming Investor

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage.

United statesNew yorkKimpton epic hotelFontainebleau hotelMolecular templates incStifel annual health care conferenceLotte new york palace hotelLive presentationShiga like toxinLooking statementsPrivate securities litigation reform actMolecular templatesSafe harborMolecular templateNasdaq mtemMolecular templates